Posted:
12/18/2024, 8:02:37 AM
Location(s):
Redwood City, California, United States ⋅ California, United States
Experience Level(s):
Internship
Field(s):
Operations & Logistics
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.
Come spend your summer working with passionate colleagues and inspirational leaders, all while gaining world-class experience in one of the fast-growing biotechs in the Bay Area.
Development Operations is responsible for ensuring that the various functions within the company that strategize, plan, and execute Corcept’s clinical (i.e., in-human) research programs have the budgetary, strategic planning, and scientific communications support necessary to perform their activities efficiently and effectively. This internship will work in two departments within Development Operations: Program Management and Development Finance & Sourcing.
The Program Management Department is responsible for two important activities. First, the department organizes and manages therapeutic area program teams that discuss, prioritize, and propose strategies to develop the company’s clinical assets. Once these strategies are approved for execution, the Program Management Department is then responsible for developing and managing the tactical plans and timelines used to bring the approved strategies to fruition.
The Development Finance & Sourcing Department is responsible for determining how much the company’s clinical studies should and will cost, and then negotiating contracts and agreements with various corporate partners who provide services and support to our clinical teams.
The Development Operations Intern will work on projects for both the Program Management and Development Finance & Sourcing Departments, in addition to providing general support to the head of Development Operations.
Responsibilities:
Preferred Skills, Qualifications and Technical Proficiencies:
Preferred Education and Experience:
The pay range that the Company reasonably expects to pay for this headquarters-based position is $25/hr - $31/hr; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
Applicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link.
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Please visit our website at: https://www.corcept.com/
Corcept is an Equal Opportunity Employer
Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.
Website: https://corcept.com/
Headquarter Location: Menlo Park, California, United States
Employee Count: 101-250
Year Founded: 1998
IPO Status: Public
Last Funding Type: Post-IPO Equity
Industries: Biotechnology ⋅ Medical ⋅ Pharmaceutical